gutflix
GI learning, personalised

Summary

TIME TO EFFECT OF BIOLOGICS AND SMALL MOLECULES IN MODERATELY TO SEVERELY ACTIVE LUMINAL CROHN'S DISEASE – A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

Jakob Benedict Seidelin

UEG Week Copenhagen 2023 Poster

IBD

October 16, 2023

Network meta-analysis of 61 studies (17,436 patients) found infliximab 5 mg/kg, with or without azathioprine, ranked highest for early clinical response and remission in moderately to severely active Crohn's disease, particularly in bio-naïve patients.

KEY POINTS

- Infliximab 5 mg/kg combined with azathioprine or as monotherapy ranked highest for inducing clinical response (CDAI-70) and clinical remission (CDAI ≤150) at week 2.
- Infliximab 5 mg/kg was significantly superior to adalimumab 160/80 mg, adalimumab 80/40 mg, certolizumab 400 mg, and risankizumab 1200 mg and 600 mg for early response at week 2.
- Findings remained consistent through week 6 in the overall population and bio-naïve patients.
- For bio-exposed patients, adalimumab 160/80 mg and ustekinumab 6 mg/kg ranked highest at week 4 for both clinical response and remission, though no infliximab 5 mg/kg data were available for this population.
- This systematic review and Bayesian network meta-analysis comparing advanced therapies may inform treatment selection decisions for patients with moderately to severely active luminal Crohn's disease.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/bb8cca6a-743c-11ee-8736-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.